IngredientsLucuma, botanically classified as Pouteria lucuma, is a South American species belonging to the Sapotaceae family. The accepted current name in modern botanical literature is Pouteria lucuma (Ruiz & Pav.) Kuntze, although the fruit was initially known as Lucuma bifera Molina, with other historic binomial names including Achras lucuma Ruiz and Pavón, Lucuma obovata Kunth, and Pouteria insignis Baehni. According to the Royal Botanic Gardens, Kew (Plants of the World Online), Pouteria lucuma is now treated as a synonym of the accepted name Lucuma bifera. The species belongs to the family Sapotaceae within the order Ericales. Because of wide generic concepts, the genus Pouteria includes 304 species with pantropical distributions.
The common name "lucuma" is used throughout the scientific and trade literature. It is known as logma in the Bolívar region of Ecuador, lohma or louma in the Cotopaxi region of Ecuador, lucma or lucmo throughout Ecuador, lucumo in the Lima region of Peru, maco or rucma in Colombia, and mamón in Costa Rica. The current common name, lucuma, is a derivative of these indigenous names.
Pouteria lucuma is a fruit tree of the family Sapotaceae of the order Ericales native to the Andean Valley of South America. It is native to the Andean valleys of Colombia, Ecuador, Peru, Bolivia, and northern Chile. The area of origin is located in the Andes at temperate elevations of 2,700–3,000 m (8,900–9,800 ft).
The fruits grow on evergreen trees reaching 8 to 15 meters in height and have been historically foraged as a food source since ancient times. Lucuma trees are productive, producing between 200 and 500 fruits per year, and each fruit takes around 8 to 9 months to ripen after pollination. The fruits average 7 to 10 centimeters in length and 4 to 6 centimeters in diameter and have an oblate, oblong, or round shape, tapering to a point on the non-stem end. Underneath the surface, the golden yellow flesh can be firm, dense, dry, or soft, depending on the variety and maturity; ripe lucuma generally has a powdery, crumbly, and starchy consistency. The fruit is commonly used in Peruvian desserts, especially ice cream, for its unique flavor, often described as resembling maple, butterscotch, or sweet potato.
Lucuma can be categorized into two subgroups known as hard or silk fruits. The version most commonly sold in fresh markets belongs to the silk fruit subgroup, or Lucuma de Seda, as the flesh is softer, sweeter, and more palatable. Most of the crop is usually used in dehydrated or frozen form since the soft flesh of the fresh fruit is easily damaged, making transportation difficult.
Lucuma was used as a subsistence crop by the native peoples of coastal Chile and Peru as early as 700 BC. Some sources indicate an even older presence: the oldest evidence of lucuma usage comes from seeds obtained from Complex II (between 8600 BC and 5600 BC) in the Guitarrero Cave in the Callejón de Huaylas in Ancash, Peru. According to archaeological research, lucuma was domesticated in the inter-Andean valleys of pre-Inca civilizations in countries like Ecuador, Peru, and Chile, where its consumption and the use of the tree's wood are extensively documented in the pictorial representations of native peoples.
There is some evidence it was actively cultivated by the Moche empire around 200 AD, who irrigated large numbers of trees for harvest. Representations of lúcuma have been found on ceramics at burial sites of the indigenous people of coastal Peru. The Moche people had a fascination with agriculture and often chose to represent fruits and vegetables, including lúcuma, in their art. The fruit was first seen and reported by Europeans in Ecuador in 1531.
In Inca mythology, lucuma represents fertility. The fruit was an important part of fertility rituals of these peoples, as its consumption was thought to promote lactation in new mothers. In its native areas, lucuma has been traditionally used for promoting lactation in women after giving birth; however, there is very little scientific evidence corroborating this claim.
The Incas used dried lucuma fruit as a natural sweetener, which is why it is often called "gold of the Incas" by Peruvians. The fruit has been used for at least 2,000 years, pre-dating even the use by the Incas. Historically, the trees have provided food in times of shortage of other crops, so can be seen as "insurance" against crop failure. Villages in Ecuador and Peru have traditionally had one or more trees by houses or in the vicinity of the settlement; traditional use has also been recorded as chicken feed or baby food.
Lucuma is commercially available in several forms:
A study analyzing the nutritional composition, antioxidant capacity, and fatty acid profile of lucuma fruit from a high-altitude valley in Bolivia found that proximate analysis revealed high levels of carbohydrates (41.7%), dietary fiber (2.4%), and protein (6.9%). The fruit's fatty acid profile showed a healthy omega-6:omega-3 ratio of 0.21.
Lucuma powder contains complex carbohydrates, dietary fiber (both soluble and insoluble), antioxidants including polyphenols, and trace minerals such as calcium, potassium, iron, niacin, and vitamin C.
Results from characterization studies on three biotypes of the lucuma mesocarp showed significant amounts of sugars (119.4–344 mg total sugars g−1 DW) and organic acids (44.4–30.0 mg g−1 DW) and functional associated compounds such as ascorbic acid (0.35–1.07 mg g−1 DW), total phenolics (0.7–61.6 mg GAE g−1 DW), and total carotenoids (0.22–0.50 mg β-carotene g−1 DW).
A 2021 study published in the journal Molecules (Masullo et al., University of Salerno) performed in-depth metabolite profiling of both the pulp and skin of P. lucuma using high-resolution LC-ESI-Orbitrap-MS analysis. The careful analysis of accurate masses, molecular formulas, and ESI/MS spectra allowed identification of specialized metabolites belonging to phenolic, flavonoid, and polar lipid classes. LC-MS analysis highlighted some flavonoids tentatively identified as belonging to the class of flavan-3-ols: gallocatechin, epigallocatechin, catechin, epicatechin, gallocatechin gallate; dihydroflavonols: ampelopsin and taxifolin; as well as flavonols. Glycosylated flavonols were identified, including myricetin-O-deoxyglycoside and quercetin-O-deoxyglycoside. The study identified 36 compounds within the pulp extract. Notably, 16 lipid compounds were identified for the first time in lucuma, including oxylipins, glycolipids, and phospholipids.
The LC-MS profile of the skin extract showed eight main ion peaks defined as phenolics, distinguishable into galloyl 1-O-glucopyranoside, ellagic acid, flavonoids, as well as polar lipids characterized by the presence of oxylipins and a galactolipid. The skin extract revealed a high phenolic content (560.69 mg GAE/g extract) and strong antioxidant activity, particularly from compounds like taxifolin. The two main flavonoid substances isolated were eriodictyol and taxifolin; taxifolin demonstrated high radical scavenging abilities, with a TEAC value of 3.53.
The total phenolic content found in the lucuma fruit is noteworthy: the total phenolic content of lucuma fruit ranged up to 11.4 mg/g of sample dry weight, the highest among the Peruvian fruits examined in one study. However, in that same study, no individual phenolic compound was detected in lucuma fruit and powder by HPLC analysis, indicating that the phenolics present may exist in forms not easily resolved by standard HPLC methods or may be below the detection limits of individual-compound assays.
Antioxidant assays identified significant amounts of polyphenols, flavonoids, and carotenoids, known for their antioxidant and anti-inflammatory properties. Lucuma is especially strong in lutein, a carotenoid group that gives lucuma its yellow color and is said to promote eye health and eyesight.
Lucuma nut oil (LNO) is a mixture of fatty acids, 99.7% of which were characterized by GC-MS analysis. Major components of LNO (w/w) are linoleic acid (38.9%), oleic acid (27.9%), palmitic acid (18.6%), stearic acid (8.9%), and γ-linolenic acid (2.9%).
A separate study on lucuma seed oil (LSO) identified additional bioactive constituents. Several compounds were tentatively identified, such as fatty acids, fatty alcohols, carotenes, phytosterols, and tocopherols. A representative result was the high amount of β-sitosterol at 851.49 ± 1.29 mg/100 g of LSO, followed by stigmasterol at 75.42 ± 1.02 mg/100 g. Metabolites tentatively identified in Pouteria lucuma seed oil have been linked to healthy properties based on the high amount of β-sitosterol present.
The total antioxidant activity of the Bolivian lucuma biotype was determined using the ABTS method at the ripe stage (3.6 µmol TE/g dw), and the antioxidant status assessed by FRAP was 5.7 µmol TE/g dw.
Important in vitro antioxidant and antihyperglycemic properties were found, providing the base for standardization of lucuma harvest and postharvest focused not only on the enhancement of sensory but functional properties. Overall, evidence for lucuma's antioxidant activity rests entirely on in vitro compositional assays (DPPH, ABTS, FRAP, TEAC). No human clinical trials have measured antioxidant status following lucuma consumption. The strength of evidence at this level is therefore preliminary — in vitro only.
The principal published evidence for lucuma's effect on blood sugar comes from a 2009 study published in the Journal of Medicinal Food (Pinto et al.), which used strictly in vitro methods. Water and 12% ethanol extracts of native Peruvian fruits including lucuma were evaluated for total phenolics, antioxidant activity, and functionality such as in vitro inhibition of alpha-amylase, alpha-glucosidase, and angiotensin I-converting enzyme (ACE) relevant for potential management of hyperglycemia and hypertension linked to type 2 diabetes. Aqueous extracts from lucuma and Algarrobo had the highest α-glucosidase inhibitory activities among the fruits studied. Alpha-glucosidase is the intestinal enzyme responsible for converting complex carbohydrates into monosaccharides; its inhibition delays glucose absorption and blunts postprandial blood sugar spikes — the same mechanism exploited by prescription agents such as acarbose.
A 2016 study in Food Chemistry (Fuentealba et al.) examined three biotypes of lucuma mesocarp. The α-amylase and α-glucosidase inhibitory activities were in the range of 0.68 to 1.11 and 0.16 to 0.17 mg IC50, respectively. Two biotypes (Rosalia and Leiva) of Andean lucuma fruit at edible ripeness reached 86.7 and 64.5% inhibition of α-amylase and 59.3 and 48.1% inhibition of α-glucosidase with 2 mg and 10 g of sample, respectively.
Regarding glycemic index (GI), lucuma is often claimed to have a low glycemic index, which means that it would raise blood sugar levels to a much lower extent than other sweeteners like pure sugar; however, no studies have confirmed lucuma's low GI score. Lucuma is higher in complex carbohydrates (starches and fiber) than simple carbohydrates (sugars). Complex carbohydrates are harder to digest and therefore less likely to result in blood sugar spikes than simple carbohydrates. These in vitro results point to the excellent potential of Peruvian fruits for food-based strategies for complementing effective antidiabetes solutions based on further animal and clinical studies.
Evidence strength: All antidiabetic evidence is in vitro only. There are no published human clinical trials evaluating lucuma's effect on glycemic response, HbA1c, insulin sensitivity, or diabetes outcomes. The in vitro findings are hypothesis-generating only.
The same 2009 Journal of Medicinal Food study (Pinto et al.) evaluated the potential of lucuma to inhibit angiotensin I-converting enzyme (ACE) in vitro. ACE inhibition is a well-established mechanism for reducing blood pressure, and it is the basis of a major class of antihypertensive drugs. Papayita arequipeña and Algarrobo had significant ACE inhibitory activities reflecting antihypertensive potential — importantly, lucuma was not identified as one of the strongest ACE inhibitors in that comparative panel, though it did exhibit measurable enzyme-inhibitory activity. Studies have reported that lucuma can inhibit the function of ACE, an enzyme involved in blood pressure management, and as a result lucuma may help reduce blood pressure; although the first findings are encouraging, additional study is needed to establish these advantages for human heart health.
Thanks to the polyphenols it contains, lucuma may help protect the heart from cardiovascular disease, contributing to lowering blood pressure; these properties are still under study, although early results are promising.
Evidence strength: In vitro only. No animal or human studies specifically and exclusively testing lucuma for blood pressure or cardiovascular outcomes have been published to date.
The most developed body of experimental (though still pre-clinical) research on lucuma concerns the wound-healing properties of its nut oil. The key study is by Rojo et al. (2010), published in the Journal of Cosmetic Dermatology (Rutgers University, New Brunswick, NJ). Cell migration, angiogenesis, inflammation, and extracellular matrix remodeling are key events in wound healing. Natural products, including fatty acids, can accelerate wound healing by modulating these events. This study aimed to evaluate the effect of lucuma nut oil (LNO) on fibroblasts migration, angiogenesis, inflammation, bacterial and fungal growth, and wound healing.
In vitro studies showed that LNO significantly promoted migration and vinculin expression in human fibroblasts. LNO decreased LPS-induced nitric oxide production and did not display significant antibacterial or antifungal effects. LNO induced tail fin regeneration in transgenic zebrafish larvae 48 hours after tail fin amputation and significantly accelerated cutaneous wound closure in CD-1 mice. The researchers concluded that natural fatty acids from P. lucuma nut promote skin regeneration and thus may have applications in medicine and skin care.
The researcher described the mechanistic basis: "The oil of lucuma seed basically has three effects: it increases the re-growth of endothelial cells; fibroblast migration, and tissue regeneration, and also displays anti-inflammatory effect. This is important since wound closure and skin wrinkling are both intimately related to the migration of specific cells in our skin called fibroblasts." In addition to increasing fibroblast migration, the extract from the seed of Pouteria lucuma can help increase the expression of elastin. "The lack of elastin, or the decrease in elastin fibres, is one of the main reasons for wrinkles to occur."
LNO increased migration of fibroblast cells in a dose-dependent manner. No activity was found in the fruit or peel extract, indicating that the wound-healing properties are specific to the seed oil fraction rather than the edible pulp.
The in vivo wound-healing effect of lucuma nut oil was evaluated during 11 days of topical application of LNO at 200, 500, and 1000 µg/wound in CD-1 mice.
Preliminary studies have suggested that the essential oil obtained from the lucuma nut promotes wound healing and skin regeneration, and it may have potential nutraceutical and cosmetic applications.
Evidence strength: Pre-clinical — in vitro cell studies and animal models (zebrafish larvae; CD-1 mice). No human clinical wound-healing trials have been published to date.
The 2021 Molecules study (Masullo et al.) represented the first comprehensive metabolite profiling of the lucuma skin fraction. No prior study had been reported on the skin, which represents an important agricultural waste due to the high demand for lucuma. The extracts of pulp and skin were analyzed by LC-ESI/LTQOrbitrap/MS/MS in negative ion mode; the careful analysis allowed identification of specialized metabolites belonging to phenolic, flavonoid, and polar lipid classes. The skin demonstrated strong antioxidant activity, particularly associated with taxifolin, making it a potential source of value-added ingredients from industrial processing waste.
The available scientific literature does not include formal dose-finding or dose-response human clinical studies for lucuma as a supplement. The following dosages appear only in the experimental studies identified:
There is little research available to determine the safety of lucuma use over a long period of time. As with any substance, caution should be taken when consuming lucuma in large portions consistently.
Thermal processing may affect polyphenol content and bioavailability in processed lucuma products such as dried powder.
On carbohydrate and sugar load: while lucuma may be a healthier option than other sweeteners, it still has enough sugars that it should not be consumed in large quantities. It may be more diabetes-friendly than sugar due to complex carbs and fiber, but clinical evidence is insufficient to confirm safety or efficacy in blood sugar control.
Regarding the seed oil (LNO), no formal systemic toxicology studies specifically for lucuma nut oil in humans have been published. The seed oil studies performed to date have been pre-clinical. A high amount of β-sitosterol (851.49 ± 1.29 mg/100 g of LSO) was identified in lucuma seed oil, and these metabolites have been linked to healthy properties based on the high amount of β-sitosterol present. β-Sitosterol is a widely studied phytosterol with an established general safety profile in the literature.
No drug interaction studies involving lucuma preparations have been published. Lucuma powder is marketed for its potential health benefits, including antioxidant properties, fiber content, and possible effects on blood sugar regulation. However, research is still in its early stages, with limited clinical trials available. Given its in vitro α-glucosidase inhibitory activity, theoretical additive effects with antidiabetic medications are plausible but have not been studied clinically.
Lucuma has a well-documented history as a traditional food and cultural symbol in Andean South America, with archaeological use traceable to at least 700 BC and possibly to prehistoric times. Its nutritional profile — including dietary fiber, complex carbohydrates, carotenoids (notably lutein), vitamin C, polyphenols, and flavonoids — is reasonably well characterized through compositional studies. The fruit's seed oil has been characterized chemically as rich in linoleic acid, oleic acid, and phytosterols, and shows pre-clinical promise in wound-healing models.
However, research is still in its early stages, with limited clinical trials available; most data comes from compositional analyses and in vitro enzymatic assays. Every health-related claim currently circulating — relating to blood sugar regulation, antihypertensive effects, wound healing, or antioxidant protection in vivo — is supported only by in vitro evidence and/or animal pre-clinical models. These in vitro results point to the excellent potential of Peruvian fruits for food-based strategies for complementing effective antidiabetes and antihypertension solutions based on further animal and clinical studies. Robust human clinical trials are absent from the published literature as of the current date.
Health conditions that Lucuma may help support.
Body systems that Lucuma may help support.
Go back